GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
The request stemmed from a 2024 lawsuit by Rampart alleging Egg Medical had infringed its patent
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
NewCo’s pipeline includes five investigational medicines
Subscribe To Our Newsletter & Stay Updated